Modern Diagnostic and Research Centre reported a 6.63% revenue increase to ₹83.11 crore for FY26. However, net profit dropped 41.73% to ₹5.25 crore due to rising expenses. A significant ₹17.45 crore of IPO funds remain unutilized, primarily for medical equipment.
Modern Diagnostic and Research Centre Ltd. FY26 Results
Modern Diagnostic revenue grew 6.63% to ₹83.11 crore in FY26, while net profit fell 41.73% to ₹5.25 crore. Reader Takeaway: Revenue up, but profit down; monitor IPO fund deployment for growth. ## What just happened Modern Diagnostic and Research Centre Ltd. reported its financial results for the year ended March 31, 2026. The company saw its revenue from operations increase by 6.63% year-over-year, reaching ₹83.11 crore. However, this top-line growth did not translate into bottom-line profit. Net profit saw a significant decline of 41.73%, falling to ₹5.25 crore from ₹9.01 crore in the previous fiscal year. This profit drop was attributed to total expenses rising to ₹78.15 crore from ₹65.93 crore. ## Why this matters The decline in net profit and a contraction in the net profit margin to 6.32% from 11.56% indicate increased cost pressures or reduced operational efficiency relative to revenue growth. For investors, the key concern is the substantial unutilized IPO proceeds of ₹17.45 crore, earmarked for purchasing medical equipment. The deployment of these funds will be crucial for future capacity expansion and revenue generation. ## The backstory Modern Diagnostic and Research Centre Ltd. is a diagnostic and research services provider. The company had previously raised funds through an Initial Public Offering (IPO), with a portion of these funds designated for specific capital expenditure, including medical equipment and working capital. ## What changes now Investors will be closely watching the company's upcoming quarterly results to see if management can control costs, improve margins, and effectively deploy the remaining IPO funds. The unmodified audit opinion provides a layer of confidence in the reported financials. ## Risks to watch The primary risks include the continued pressure on profitability due to rising expenses, the pace and effectiveness of utilizing IPO proceeds for growth initiatives, and the potential impact of competitive pressures in the diagnostic sector. ## Peer comparison (No peer comparison data available in the filing). ## Context metrics (time-bound) For the year ended March 31, 2026: * Revenue from operations: ₹83.11 crore (₹77.95 crore in FY25) * Net Profit: ₹5.25 crore (₹9.01 crore in FY25) * EPS (Basic): ₹3.48 (₹8.19 in FY25) * Unutilized IPO proceeds: ₹17.45 crore ## What to track next Investors should track the company's progress in deploying the unutilized IPO funds for medical equipment purchases and assess whether profitability margins can be restored in future financial periods.
Get stock alerts instantly on WhatsApp
Quarterly results, bulk deals, concall updates and major announcements delivered in real time.
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.
